-
Sienna to acquire US-based Sevident Inc’s ground-breaking “NETs” molecular captureplatform.
-
Enables Sienna to expand into the rapidly growing liquid biopsy and exosome space,including diagnostic and prognostic tests for a range of cancers.
-
Acquisition of entirely new technology platform diversifies and strengthens Sienna’s product pipeline and creates new scientific and commercial opportunities.
For more information, download the attached PDF.
Download this document
